Nathanael S Gray Selected Research

Doublecortin-Like Kinases

1/2021	Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.
10/2020	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
1/2020	Discovery of a selective inhibitor of doublecortin like kinase 1.
1/2020	Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nathanael S Gray Research Topics

Disease

136	Neoplasms (Cancer) 10/2022 - 03/2006
20	Lung Neoplasms (Lung Cancer) 01/2022 - 05/2008
19	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 12/2009
11	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2011
11	Neuroblastoma 01/2021 - 05/2008
11	Leukemia 01/2020 - 02/2009
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 09/2010
7	Parkinson Disease (Parkinson's Disease) 01/2017 - 04/2011
6	Lymphoma (Lymphomas) 01/2022 - 01/2007
6	Inflammation (Inflammations) 01/2020 - 03/2009
6	Infections 01/2019 - 01/2016
6	Melanoma (Melanoma, Malignant) 01/2019 - 12/2009
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 02/2006
4	Multiple Myeloma 01/2022 - 05/2009
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 01/2016
4	Ewing Sarcoma (Sarcoma, Ewing) 10/2021 - 03/2012
4	Ovarian Neoplasms (Ovarian Cancer) 10/2020 - 01/2016
4	Disease Progression 01/2020 - 01/2018
4	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2018 - 01/2007
4	Carcinogenesis 01/2018 - 03/2008
4	Adenocarcinoma of Lung 01/2017 - 12/2010
3	Immune System Diseases (Immune Disorders) 12/2021 - 08/2015
3	Adenocarcinoma 01/2021 - 01/2020
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2016
3	Dengue (Dengue Fever) 01/2019 - 01/2016
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 10/2018
3	Osteosarcoma (Osteogenic Sarcoma) 02/2016 - 09/2012
3	Aneuploidy (Aneuploid) 09/2013 - 03/2008
2	Tauopathies 01/2022 - 01/2019
2	Stomach Neoplasms (Stomach Cancer) 12/2021 - 01/2021
2	Cholangiocarcinoma 12/2021 - 01/2018
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2021 - 01/2018
2	Chordoma 01/2021 - 01/2019
2	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2015

Drug/Important Bio-Agent (IBA)

75	Phosphotransferases (Kinase)IBA 04/2022 - 12/2007
27	Pharmaceutical PreparationsIBA 01/2022 - 12/2007
25	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2006
11	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 07/2012
11	Transcription Factors (Transcription Factor)IBA 01/2021 - 12/2013
11	Anaplastic Lymphoma KinaseIBA 10/2018 - 05/2008
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 09/2011
10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 12/2009
10	Adenosine Triphosphate (ATP)IBA 12/2021 - 01/2011
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 12/2009
9	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 02/2006
8	CrizotinibIBA 12/2015 - 02/2010
7	Oncogene Proteins (Oncogene Protein)IBA 01/2022 - 01/2014
7	CytokinesIBA 12/2021 - 05/2009
7	ibrutinibIBA 11/2021 - 10/2015
7	Protein Kinases (Protein Kinase)IBA 10/2020 - 10/2012
7	Leucine (L-Leucine)FDA Link 01/2017 - 04/2011
6	Tyrosine (L-Tyrosine)FDA Link 04/2022 - 03/2010
6	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 03/2009
6	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 03/2012
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2018 - 06/2011
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 05/2008
6	Interleukin-10 (Interleukin 10)IBA 01/2018 - 03/2009
5	Antiviral Agents (Antivirals)IBA 01/2019 - 03/2017
5	Sirolimus (Rapamycin)FDA Link 01/2014 - 03/2009
4	Small Interfering RNA (siRNA)IBA 01/2022 - 10/2008
4	LigandsIBA 12/2021 - 08/2015
4	SaltsIBA 01/2021 - 01/2016
4	Doublecortin-Like KinasesIBA 01/2021 - 01/2020
4	Mitogen-Activated Protein Kinase 7IBA 01/2020 - 10/2014
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 12/2010
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 12/2021 - 01/2021
3	Peptidylprolyl Isomerase (Prolyl Isomerase)IBA 01/2021 - 01/2020
3	AntibodiesIBA 01/2019 - 01/2018
3	Biological ProductsIBA 12/2018 - 07/2008
3	Mitogen-Activated Protein KinasesIBA 01/2018 - 12/2009
3	VemurafenibIBA 01/2018 - 03/2015
3	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2014
3	NVP-TAE684IBA 02/2016 - 01/2007
3	ALW-II-41-27IBA 01/2016 - 05/2014
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2016 - 03/2010
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2015 - 03/2009
3	AZD 6244IBA 11/2014 - 12/2009
3	Imatinib Mesylate (Gleevec)FDA Link 06/2014 - 10/2010
3	TOR Serine-Threonine KinasesIBA 01/2012 - 10/2010
2	src-Family KinasesIBA 01/2022 - 09/2014
2	Immunomodulating AgentsIBA 01/2022 - 01/2021
2	tau Proteins (tau Protein)IBA 01/2022 - 01/2019
2	Janus KinasesIBA 12/2021 - 08/2015
2	venetoclaxIBA 11/2021 - 01/2019
2	abemaciclibIBA 11/2021 - 10/2021
2	RNA Polymerase II (RNA Polymerase B)IBA 10/2021 - 01/2021
2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2021 - 08/2015
2	Cyclin-Dependent Kinase 9IBA 01/2021 - 01/2018
2	YKL-05-099IBA 01/2021 - 01/2020
2	YKL-5-124IBA 01/2021 - 01/2020
2	Gemcitabine FDA Link 01/2021 - 01/2017
2	Brachyury protein (Brachyury)IBA 01/2021 - 01/2019
2	phosphatidylinositol 5-phosphateIBA 03/2020 - 01/2020
2	LipidsIBA 01/2020 - 07/2012
2	Drug CombinationsIBA 01/2020 - 11/2014
2	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2018

Therapy/Procedure

55	Therapeutics 10/2022 - 10/2008
6	Drug Therapy (Chemotherapy) 01/2021 - 10/2008
4	Immunotherapy 01/2021 - 01/2018
2	Oral Administration 11/2021 - 11/2014